Lars Jørgen Østergaard

Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine : implications for antiretroviral therapy programs in resource-limited settings. / Cozzi-Lepri, Alessandro; Phillips, Andrew N; Martinez-Picado, Javier; Monforte, Antonella d'Arminio; Katlama, Christine; Eg Hansen, Ann-Brit; Horban, Andrzej; Bruun, Johann; Clotet, Bonaventura; Lundgren, Jens D; EuroSIDA Study Group (Lars Østergaard, member).

In: Journal of Infectious Diseases, Vol. 200, No. 5, 01.09.2009, p. 687-97.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Cozzi-Lepri, A, Phillips, AN, Martinez-Picado, J, Monforte, ADA, Katlama, C, Eg Hansen, A-B, Horban, A, Bruun, J, Clotet, B, Lundgren, JD & EuroSIDA Study Group (Lars Østergaard, member) 2009, 'Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings', Journal of Infectious Diseases, vol. 200, no. 5, pp. 687-97. https://doi.org/10.1086/604731

APA

Cozzi-Lepri, A., Phillips, A. N., Martinez-Picado, J., Monforte, A. DA., Katlama, C., Eg Hansen, A-B., Horban, A., Bruun, J., Clotet, B., Lundgren, J. D., & EuroSIDA Study Group (Lars Østergaard, member) (2009). Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. Journal of Infectious Diseases, 200(5), 687-97. https://doi.org/10.1086/604731

CBE

Cozzi-Lepri A, Phillips AN, Martinez-Picado J, Monforte ADA, Katlama C, Eg Hansen A-B, Horban A, Bruun J, Clotet B, Lundgren JD, EuroSIDA Study Group (Lars Østergaard, member). 2009. Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings. Journal of Infectious Diseases. 200(5):687-97. https://doi.org/10.1086/604731

MLA

Vancouver

Author

Cozzi-Lepri, Alessandro ; Phillips, Andrew N ; Martinez-Picado, Javier ; Monforte, Antonella d'Arminio ; Katlama, Christine ; Eg Hansen, Ann-Brit ; Horban, Andrzej ; Bruun, Johann ; Clotet, Bonaventura ; Lundgren, Jens D ; EuroSIDA Study Group (Lars Østergaard, member). / Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine : implications for antiretroviral therapy programs in resource-limited settings. In: Journal of Infectious Diseases. 2009 ; Vol. 200, No. 5. pp. 687-97.

Bibtex

@article{b6edb00d02284c00bce81fa35f76bbde,
title = "Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings",
abstract = "BACKGROUND: Because changes in antiretroviral therapy in resource-limited settings (RLSs) are delayed until patients experience immunological or clinical failure, it is important to be able to estimate the consequences in terms of accumulation of thymidine analogue (TA) mutations (TAMs).METHODS: The study included patients in EuroSIDA with 2 available genotypic resistance tests (GRTs) (human immunodeficiency virus [HIV] RNA level, >500 copies/mL in any measure between tests), provided that the first GRT was performed after the first virological failure of a TA and that the same TA was continued until the second GRT.RESULTS: At the time of the first GRT in a pair (t0), 1 year after virological failure, a median of 3 TAMs were detected, mutations 41L and 215Y in 65% of pairs and 67N in 52%. Overall, 126 TAMs were accumulated during 548 person-years of follow-up (PYFUs) (1/4.3 years; 95% confidence interval, 3.7-5.0 years). Greater predicted activity of the TA at t0, TAM profile 2 (TAM2; vs TAM profile 1 [TAM1]) profiles at t0, use of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) at t0 (vs combined NNRTI and protease inhibitor), and acquisition of HIV infection through heterosexual (vs homosexual) contacts were associated with a faster rate of TAM accumulation.CONCLUSIONS: Although the estimated rate of TAM accumulation was lower than anticipated, all possible efforts should be continued to increase the availability of drug options in RLSs.",
keywords = "Adolescent, Adult, Aged, Anti-HIV Agents, Antiretroviral Therapy, Highly Active, Drug Resistance, Viral, Female, HIV, HIV Infections, Humans, Male, Microbial Sensitivity Tests, Middle Aged, Mutation, Missense, Stavudine, Young Adult, Zidovudine",
author = "Alessandro Cozzi-Lepri and Phillips, {Andrew N} and Javier Martinez-Picado and Monforte, {Antonella d'Arminio} and Christine Katlama and {Eg Hansen}, Ann-Brit and Andrzej Horban and Johann Bruun and Bonaventura Clotet and Lundgren, {Jens D} and {EuroSIDA Study Group (Lars {\O}stergaard, member)} and {\O}stergaard, {Lars J{\o}rgen}",
year = "2009",
month = sep,
day = "1",
doi = "10.1086/604731",
language = "English",
volume = "200",
pages = "687--97",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "5",

}

RIS

TY - JOUR

T1 - Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine

T2 - implications for antiretroviral therapy programs in resource-limited settings

AU - Cozzi-Lepri, Alessandro

AU - Phillips, Andrew N

AU - Martinez-Picado, Javier

AU - Monforte, Antonella d'Arminio

AU - Katlama, Christine

AU - Eg Hansen, Ann-Brit

AU - Horban, Andrzej

AU - Bruun, Johann

AU - Clotet, Bonaventura

AU - Lundgren, Jens D

AU - EuroSIDA Study Group (Lars Østergaard, member)

A2 - Østergaard, Lars Jørgen

PY - 2009/9/1

Y1 - 2009/9/1

N2 - BACKGROUND: Because changes in antiretroviral therapy in resource-limited settings (RLSs) are delayed until patients experience immunological or clinical failure, it is important to be able to estimate the consequences in terms of accumulation of thymidine analogue (TA) mutations (TAMs).METHODS: The study included patients in EuroSIDA with 2 available genotypic resistance tests (GRTs) (human immunodeficiency virus [HIV] RNA level, >500 copies/mL in any measure between tests), provided that the first GRT was performed after the first virological failure of a TA and that the same TA was continued until the second GRT.RESULTS: At the time of the first GRT in a pair (t0), 1 year after virological failure, a median of 3 TAMs were detected, mutations 41L and 215Y in 65% of pairs and 67N in 52%. Overall, 126 TAMs were accumulated during 548 person-years of follow-up (PYFUs) (1/4.3 years; 95% confidence interval, 3.7-5.0 years). Greater predicted activity of the TA at t0, TAM profile 2 (TAM2; vs TAM profile 1 [TAM1]) profiles at t0, use of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) at t0 (vs combined NNRTI and protease inhibitor), and acquisition of HIV infection through heterosexual (vs homosexual) contacts were associated with a faster rate of TAM accumulation.CONCLUSIONS: Although the estimated rate of TAM accumulation was lower than anticipated, all possible efforts should be continued to increase the availability of drug options in RLSs.

AB - BACKGROUND: Because changes in antiretroviral therapy in resource-limited settings (RLSs) are delayed until patients experience immunological or clinical failure, it is important to be able to estimate the consequences in terms of accumulation of thymidine analogue (TA) mutations (TAMs).METHODS: The study included patients in EuroSIDA with 2 available genotypic resistance tests (GRTs) (human immunodeficiency virus [HIV] RNA level, >500 copies/mL in any measure between tests), provided that the first GRT was performed after the first virological failure of a TA and that the same TA was continued until the second GRT.RESULTS: At the time of the first GRT in a pair (t0), 1 year after virological failure, a median of 3 TAMs were detected, mutations 41L and 215Y in 65% of pairs and 67N in 52%. Overall, 126 TAMs were accumulated during 548 person-years of follow-up (PYFUs) (1/4.3 years; 95% confidence interval, 3.7-5.0 years). Greater predicted activity of the TA at t0, TAM profile 2 (TAM2; vs TAM profile 1 [TAM1]) profiles at t0, use of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) at t0 (vs combined NNRTI and protease inhibitor), and acquisition of HIV infection through heterosexual (vs homosexual) contacts were associated with a faster rate of TAM accumulation.CONCLUSIONS: Although the estimated rate of TAM accumulation was lower than anticipated, all possible efforts should be continued to increase the availability of drug options in RLSs.

KW - Adolescent

KW - Adult

KW - Aged

KW - Anti-HIV Agents

KW - Antiretroviral Therapy, Highly Active

KW - Drug Resistance, Viral

KW - Female

KW - HIV

KW - HIV Infections

KW - Humans

KW - Male

KW - Microbial Sensitivity Tests

KW - Middle Aged

KW - Mutation, Missense

KW - Stavudine

KW - Young Adult

KW - Zidovudine

U2 - 10.1086/604731

DO - 10.1086/604731

M3 - Journal article

C2 - 19604043

VL - 200

SP - 687

EP - 697

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 5

ER -